85 results on '"Gulamhusein, A"'
Search Results
2. Single-cell, single-nucleus, and spatial transcriptomics characterization of the immunological landscape in the healthy and PSC human liver
3. Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis
4. LBP-040 Long-term efficacy and safety of open-label seladelpar treatment in patients with primary biliary cholangitis (PBC): interimresults for 2 years from the ASSURE study
5. TOP-168-YI Urgent call to action: people living with primary sclerosing cholangitis-inflammatory bowel disease (PSC-IBD) lose 10 years of life compared to those with IBD alone
6. TOP-169 Sex, ethnicity and clinical outcomes in autoimmune hepatitis: results from a large multicenter longitudinal cohort
7. OS-018 Liver stiffness measurement by vibration-controlled transient elastography predicts adverse clinical outcomes in autoimmune hepatitis: results from a large multicenter longitudinal study
8. Predicting post-TIPSS mortality: external validation of the FIPS score in a Canadian cohort
9. Prognostic significance of liver stiffness progression in primary biliary cholangitis
10. Loss of innate and adaptive effector lymphocytes is associated with diminished globe score prognosis in patients with primary biliary cholangitis
11. The socioeconomic status, epidemiology, and outcomes of people living with primary sclerosing cholangitis-inflammatory bowel disease in Ontario, Canada: a two-decade analysis
12. Symptom burden in people living with primary biliary cholangitis does not associate with transient elastography measures
13. Peri-procedural complications in people with primary sclerosing cholangitis undergoing endoscopic retrograde cholangiopancreatography-evaluating a high-volume programme
14. A dynamic approach to modelling baseline disease status and ALT elevation over follow-up on clinical-event free survival in autoimmune hepatitis: a canadian multicentre cohort
15. Long-term obeticholic acid (OCA) for primary biliary cholangitis (PBC) in a clinical trial improved event free survival (death, liver transplant and hepatic decompensation) compared to external controls from the GLOBAL PBC real-world database
16. North American evaluation of 2519 patients with primary sclerosing cholangitis: longitudinal patterns of disease activity identify and validate stable and progressive phenotypes
17. THU-121 Harnessing synergy of ‘triple’ anti-cholestatic therapy in patients with primary biliary cholangitis
18. A dynamic approach to modelling baseline disease status and ALT elevation over follow-up on clinical-event free survival in autoimmune hepatitis: a canadian multicentre cohort
19. North American evaluation of 2519 patients with primary sclerosing cholangitis: longitudinal patterns of disease activity identify and validate stable and progressive phenotypes
20. FRI-363 - Loss of innate and adaptive effector lymphocytes is associated with diminished globe score prognosis in patients with primary biliary cholangitis
21. WED-310 - Symptom burden in people living with primary biliary cholangitis does not associate with transient elastography measures
22. WED-281 - Peri-procedural complications in people with primary sclerosing cholangitis undergoing endoscopic retrograde cholangiopancreatography-evaluating a high-volume programme
23. WED-255 - The socioeconomic status, epidemiology, and outcomes of people living with primary sclerosing cholangitis-inflammatory bowel disease in Ontario, Canada: a two-decade analysis
24. SAT-548 - Predicting post-TIPSS mortality: external validation of the FIPS score in a Canadian cohort
25. OS-073 - Prognostic significance of liver stiffness progression in primary biliary cholangitis
26. The impact of geographical region on outcomes of patients with primary biliary cholangitis from western Europe
27. Symptom burden in patients living with primary biliary cholangitis: indigenous Canadians report significantly higher PBC-40 quality of life scores
28. Durability of treatment response after 1 year of therapy with seladelpar in patients with primary biliary cholangitis (PBC): final results of an international phase 2 study
29. Symptom burden in patients living with primary biliary cholangitis: indigenous Canadians report significantly higher PBC-40 quality of life scores
30. FRI-055-Failure to normalize ALT and IgG in Autoimmune Hepatitis is associated with more advanced liver disease: Perspectives from a multi-ethnic Canadian AIH registry
31. FRI-045-Treatment of patients with primary biliary cholangitis with seladelpar for 52 weeks improves predicted transplant-free survival
32. FRI-034-Clinical phenotype of significantly elevated serum IgG4: Single center experience
33. FRI-046-Raising awareness and messaging risk in patients with primary biliary cholangitis: The rapid Global PBC Screening Test
34. FRI-055-Failure to normalize ALT and IgG in Autoimmune Hepatitis is associated with more advanced liver disease: Perspectives from a multi-ethnic Canadian AIH registry
35. PS-128-Risk of gall bladder cancer in patients with primary sclerosing cholangitis and gall bladder polyps: an opportunity to revisit the guidelines
36. FRI-056-Obeticholic acid as adjunctive therapy in Primary Biliary Cholangitis: A review of early real-world experience
37. THU-024-Methylation signatures in blood show accelerated epigenetic aging in patients with primary sclerosing cholangitis compared to healthy controls
38. PS-122-Seladelpar for the treatment of primary biliary cholangitis: Experience with 26 cirrhotic patients
39. FRI-045-Treatment of patients with primary biliary cholangitis with seladelpar for 52 weeks improves predicted transplant-free survival
40. Younger age is associated with lower transplant-free survival relative to a general population in patients with Primary Biliary Cholangitis
41. Histologic stage is a stronger predictor of transplant free survival than APRI and FIB-4 in patients with primary biliary cholangitis
42. FRI-046-Raising awareness and messaging risk in patients with primary biliary cholangitis: The rapid Global PBC Screening Test
43. PS-128-Risk of gall bladder cancer in patients with primary sclerosing cholangitis and gall bladder polyps: an opportunity to revisit the guidelines
44. FRI-056-Obeticholic acid as adjunctive therapy in Primary Biliary Cholangitis: A review of early real-world experience
45. FRI-034-Clinical phenotype of significantly elevated serum IgG4: Single center experience
46. THU-024-Methylation signatures in blood show accelerated epigenetic aging in patients with primary sclerosing cholangitis compared to healthy controls
47. Histologic stage is a stronger predictor of transplant free survival than APRI and FIB-4 in patients with primary biliary cholangitis
48. Younger age is associated with lower transplant-free survival relative to a general population in patients with Primary Biliary Cholangitis
49. Increase in age at diagnosis of Primary Biliary Cholangitis over the last 40 years
50. Increase in age at diagnosis of Primary Biliary Cholangitis over the last 40 years
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.